News | Nuclear Imaging | April 20, 2016

Agreement will bring proton therapy, MR-guided linear accelerators and PET/MR technology to U.K. hospital

Mirada Medical, The Christie Hospital, England, PET-MRI, radiation therapy

April 20, 2016 — Mirada Medical announced a new agreement to work with the clinicians and physicists at The Christie Hospital in Manchester, England, a world-renowned centre for complete cancer care. The Christie is the only U.K. hospital that will be treating cancer patients with proton therapy and magnetic resonance imaging (MRI)-guided linear accelerators (LINAC), whilst benefiting from the latest advancements in diagnostics with positron emission tomography (PET)/MRI.

With Mirada specializing in software to enable collaboration between departments and treatment methods, this is a natural relationship that will support fundamental changes in treatment protocols, reducing time to treatment whilst improving clinical confidence and efficacy.

“We have chosen Mirada as strategic partner to develop multimodality imaging solutions because of the quality of their software, allowing rapid translation of novel techniques into our clinic while also providing the possibility to efficiently integrate workflows for the different treatment techniques that are available at our site,” said Prof. Marcel Van Herk, chair in radiotherapy physics at the University of Manchester and The Christie NHS Foundation Trust.

For more information: www.mirada-medical.com


Related Content

News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Radiology Imaging

Jan. 21, 2026 — Cathpax, a spin-off of the Lemer Pax group that designs, develops and commercializes team-wide, full ...

Time January 22, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
News | Radiopharmaceuticals and Tracers

Dec. 11, 2025 — Telix Pharmaceuticals Ltd. has announced a strategic clinical collaboration with Varian, a Siemens ...

Time December 11, 2025
arrow
News | Radiopharmaceuticals and Tracers

Nov. 11, 2025 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released a position paper outlining ...

Time November 12, 2025
arrow
News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
Feature | Kyle Hardner

Radiotherapy contributes to about 40% of all cancer cures but still lags behind systemic therapy in funding and ...

Time October 21, 2025
arrow
News | Radiation Oncology

Sept. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT has announced ...

Time September 05, 2025
arrow
News | Nuclear Imaging

May 5, 2025 — GE HealthCare recently announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance ...

Time May 06, 2025
arrow
Subscribe Now